Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical tria...

Full description

Bibliographic Details
Main Authors: Marcello Moccia, Roberta Lanzillo, Martina Petruzzo, Agostino Nozzolillo, Marcello De Angelis, Antonio Carotenuto, Raffaele Palladino, Vincenzo Brescia Morra
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
cladribine
real-world
treatment
relapse
disability
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00489/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00489/full

Similar Items